ÂÜŔňÂŇÂ×

Mr. Terrance McGuire brings more than 35 years of biotechnology venture capital experience as co-founder and general partner of Polaris Partners, where he has provided early-stage funding and leadership counsel for more than 80 medical and information technology companies.

Prior to starting Polaris Partners, McGuire spent seven years at Burr, Egan, Deleage & Co., investing in early stage medical and information technology companies.

McGuire currently serves on the boards of Adimab, Alector, Cyclerion and Seer. He is also a member of the boards of The Thayer School of Engineering at Dartmouth College, The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) and The Arthur Rock Center for Entrepreneurship at Harvard Business School.

He has previously served on the boards of Cubist Pharmaceuticals, Acceleron Pharma, Akamai, GlycoFi and Ironwood, among others. He was formerly chair of the National Venture Capital Association.

In 2020, McGuire was honored by the NVCA with the Outstanding Service Award. In 2015, he was listed as one of Scientific American’s Worldview “100 Visionaries who Continue to Reshape Biotechnology and the World.” He is also a recipient of the Massachusetts Society for Medical Research Award, and the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Harvard and the City of Jerusalem.

McGuire earned a BS in Physics and Economics from Hobart College, an MS in Engineering from the Thayer School at Dartmouth College, and an MBA from Harvard Business School. He was awarded honorary doctorate degrees from Ohio Wesleyan University and Canisius College for his work in translational science.